Adverse effects of antiretroviral therapy for HIV infection.

Long-term remission of HIV-1 disease can be readily achieved by combinations of antiretroviral agents. The suppression of plasma viral loads to less than the limit of quantification of the most sensitive commercially available assays (i.e., less than 50 copies/mL) and the coincident improvement in CD4 T cell counts is associated with resolution of established opportunistic infections and a decrease in the risk of new opportunistic infections. However, prolonged treatment with combination regimens can be difficult to sustain because of problems with adherence and toxic effects. All antiretroviral drugs can have both short-term and long-term adverse events. The risk of specific side effects varies from drug to drug, from drug class to drug class, and from patient to patient. A better understanding of the adverse effects of antiretroviral agents is of interest not only for HIV specialists as they try to optimize therapy, but also for other physicians who care for HIV-positive patients.

[1]  R. Hewitt Abacavir hypersensitivity reaction. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  T. Hassanein,et al.  Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Johns The other human genome: Mitochondrial DNA and disease , 1996, Nature Medicine.

[4]  W. K. Henry,et al.  Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  J. Montaner,et al.  Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy. , 2002, Journal of acquired immune deficiency syndromes.

[6]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.

[7]  A. Schwenk,et al.  Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. , 2000, European journal of medical research.

[8]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[9]  D. Skiest,et al.  Osteonecrosis in HIV: A Case‐Control Study , 2000, Journal of acquired immune deficiency syndromes.

[10]  S. Kukich Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. , 2001, MMWR. Morbidity and mortality weekly report.

[11]  R. Narins,et al.  Clinical use of the anion gap. , 1977, Medicine.

[12]  L. Roudière,et al.  Osteonecrosis of the hip, lipodystrophy and antiretroviral treatment. , 2000, AIDS.

[13]  J. Frohlich,et al.  Common problems in the management of hypertriglyceridemia. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  L. Naldi,et al.  Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis , 2001, AIDS.

[15]  P. Gabow,et al.  Diagnostic importance of an increased serum anion gap. , 1980, The New England journal of medicine.

[16]  J. Olano,et al.  Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  C. Shikuma,et al.  Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. , 1999, AIDS.

[18]  P. Gabow,et al.  The fall of the serum anion gap. , 1990, Archives of internal medicine.

[19]  R. Garry,et al.  Both necrosis and apoptosis contribute to HIV-1-induced killing of CD4 cells. , 1999, AIDS.

[20]  R. Hogg,et al.  Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[21]  E. Zafrani,et al.  Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. , 1999, Journal of hepatology.

[22]  I. G. Fantus,et al.  New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[23]  K. K. Lai,et al.  Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). , 1991, Annals of internal medicine.

[24]  D. Dieterich Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. , 1999, The American journal of medicine.

[25]  Lenzo Np,et al.  Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. , 1997 .

[26]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[27]  M. Dubé Disorders of glucose metabolism in patients infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  L. Ostrosky-Zeichner,et al.  Liposuction for protease-inhibitor-associated lipodystrophy. , 1999, The Lancet.

[29]  R. Luzzati,et al.  Riboflavine and severe lactic acidosis , 1999, The Lancet.

[30]  R. Chaisson,et al.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.

[31]  J. L. Martin,et al.  Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis , 1994, Antimicrobial Agents and Chemotherapy.

[32]  Ignacio Conget,et al.  Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study , 2001, The Lancet.

[33]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[34]  C. Schramm,et al.  Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. , 1999, European journal of anaesthesiology.

[35]  R. Chaisson,et al.  Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. , 1995, The American journal of gastroenterology.

[36]  S. Pahwa,et al.  Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac. , 2001, AIDS patient care and STDs.

[37]  Jacques P. Brown,et al.  The 2002 Canadian bone densitometry recommendations: take-home messages. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  D. Cooper,et al.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.

[39]  P. Matthews,et al.  Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease , 1993, Neurology.

[40]  H. Przyrembel,et al.  Therapy of mitochondrial disorders , 1987, Journal of Inherited Metabolic Disease.

[41]  T. Antoniou,et al.  Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[42]  M. Chevallier,et al.  Fulminant hepatitis with severe lactate acidosis in HIV‐infected patients on didanosine therapy , 1994, Journal of internal medicine.

[43]  A. Koeger,et al.  Multiple site avascular necrosis in HIV infected patients. , 1991, The Journal of rheumatology.

[44]  D. Cooper,et al.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome , 2000, AIDS.

[45]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[46]  J. Shapiro,et al.  Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. , 1997, Critical care medicine.

[47]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[48]  L. Ostrosky-Zeichner,et al.  Liposuction for protease-inhibitorassociated lipodystrophy , 1999, The Lancet.

[49]  C. Moore,et al.  Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy , 2001, AIDS.

[50]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[51]  M. Dalakas,et al.  Mitochondrial toxicity of antiviral drugs , 1995, Nature Medicine.

[52]  C. Tsai,et al.  Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides , 1994, Antimicrobial Agents and Chemotherapy.

[53]  S. Dimauro,et al.  Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an HIV-infected child treated with combination antiretroviral therapy. , 2001, The Journal of pediatrics.

[54]  V. Soriano,et al.  Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy , 2000, AIDS.

[55]  P. Gabow Disorders associated with an altered anion gap. , 1985, Kidney international.

[56]  C. Katlama,et al.  Factors affecting liver fibrosis in human immunodeficiency virus–and hepatitis C virus–coinfected patients: Impact of protease inhibitor therapy , 2001, Hepatology.

[57]  Jacques P. Brown,et al.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[58]  Mark Dybul,et al.  Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV* , 2002, Annals of Internal Medicine.

[59]  R. Reves,et al.  Riboflavin to treat nucleoside analogue-induced lactic acidosis , 1998, The Lancet.

[60]  P. Clay The abacavir hypersensitivity reaction: a review. , 2002, Clinical therapeutics.

[61]  K. Yarasheski,et al.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy , 2000, AIDS.

[62]  N. Paton,et al.  Bone Mineral Density in Patients with Human Immunodeficiency Virus Infection , 1997, Calcified Tissue International.

[63]  J. Frohlich,et al.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[64]  O. Rouvière,et al.  A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. , 1999, AIDS.

[65]  K. Brinkman,et al.  Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. , 2000, AIDS.

[66]  J. Montaner,et al.  Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  P. Giangrande,et al.  Increased bleeding associated with protease inhibitor therapy in HIV‐positive patients with bleeding disorders , 1999, British journal of haematology.

[68]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[69]  J. Arenas,et al.  Plasma carnitine insufficiency and effectiveness of L‐carnitine therapy in patients with mitochondril myopathy , 1993, Muscle & nerve.

[70]  P. Reiss,et al.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.

[71]  P. Harrigan,et al.  Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. , 2002, The New England journal of medicine.